Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study
Richard Weisler,Mark Joyce,Lora McGill,Arthur Lazarus,Johan Szamosi,Hans Eriksson,Moonstone Study Group,Mohammed Alam,Grant Belnap,Guy Brannon,John Carman,Harry Croft,Himasiri DeSilva,Bradley Diner,Michael Downing,Neil Dubin,Beal Essink,Donald Garcia,Steven Glass,Susanna Goldstein,Daniel Grosz,Arifulla Khan,Irving Kolin,Jelena Kunovac,Sidney Lerfald,Michael Levy,Arnold Licht,Adam Lowy,Azfar Malik,Laura McGill,Leslie Moldauer,Mahmoud Okasha,Nader Oskooilar,Angela Pinhiero,Robert Riesenberg,Leon Rosenberg,Dwight St Clair,Jeffrey Simon,Ward Smith,Jerry Steiert,Nicholas Vatakis,Cherian Verghese,Inna Yuryev-Golder
DOI: https://doi.org/10.1017/s1092852900020307
Abstract:Introduction: Once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy was evaluated in major depressive disorder (MDD). Method: This was an 8-week (6-week randomized-phase; 2-week drug-discontinuation/tapering phase), double-blind, parallel-group, placebo-controlled study. The primary outcome measure was Montgomery-Asberg Depression Rating Scale (MADRS) total score randomization-to-Week 6 change. Other assessments included the Hamilton Rating Scale for Depression, the Hamilton Rating Scale for Anxiety, and adverse events (AEs). Results: 723 patients were randomized: 182, 178, 179, and 184 to quetiapine XR 50, 150, 300 mg/day, and placebo, respectively. At Week 6, significant reductions occurred in MADRS score with quetiapine XR 50 mg/day (-13.56; P<.05), 150 mg/day (-14.50; P<.01) and 300 mg/day (-14.18; P<.01) versus placebo (-11.07); at Day 4, reductions for quetiapine XR (titrated to 50 or 150 mg/day according to dose group) versus placebo (-2.9) were: -4.7 (P<.01), -5.2 (P<.001), and -5.1 (P<.001), respectively. At endpoint, MADRS response (>or=50% reduction in score) was 42.7% (P<.01), 51.2% (P<.001), and 44.9% (P<or= .001) for quetiapine XR 50, 150, and 300 mg/day, respectively; 30.3% for placebo. Overall, quetiapine XR 150 mg/day provided consistently more positive secondary efficacy results than 50 mg/day and 300 mg/day versus placebo. The most common AEs in quetiapine XR-treated patients were dry mouth, sedation, somnolence, headache, and dizziness. Conclusion: In patients with MDD, quetiapine XR monotherapy (50/150/300 mg/day) is effective in reducing depressive symptoms, with improvement from Day 4 onwards. Safety and tolerability were consistent with the known profile of quetiapine.